Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

W-L Expects Neurontin Sales To Reach $800 Mil. And Hold Through 2000

Executive Summary

Warner-Lambert expects its anti-epileptic product Neurontin (gabapentin) to grow by more than 50% to $800 mil. this year and hold that level through its patent expiration year of 2000, the company said at a May 18 meeting with the New York Society of Securities Analysts.

You may also be interested in...



Warner-Lambert Neurontin Surpasses Rezulin In Sales For The First Time

Second quarter sales of Warner-Lambert's Neurontin (gabapentin) climbed 69% over the year-ago quarter, the company reported.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel